Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 240

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

Open access
Longhurst, Hilary, Cicardi, Marco, Craig, Timothy, Bork, Konrad, Grattan, Clive, Baker, James, Li, Huamin H., Reshef, Avner, Bonner, James, Bernstein, Jonathan A., Anderson, John, Lumry, William R., Farkas, Henriette, Katelaris, Constance H., Sussman, Gordon L., Jacobs, Joshua, Riedl, Marc, Manning, Michael E., Hebert, Jacques, Keith, Paul K., Kivity, Shmuel, Neri, Sergio, Levy, Donald S., Baeza, Maria L., Nathan, Robert, Schwartz, Lawrence B., Caballero, Teresa, Yang, William, Crisan, Ioana, Hernandez, María D., Hussain, Iftikhar, Tarzi, Michael, Ritchie, Bruce, Králíčková, Pavlina, Guilarte, Mar, Rehman, Syed M., Banerji, Aleena, Gower, Richard G., Bensen-Kennedy, Debra, Edelman, Jonathan, Feuersenger, Henrike, Lawo, John-Philip, Machnig, Thomas, Pawaskar, Dipti, Pragst, Ingo, Zuraw, Bruce L.·2017·New England Journal of Medicine

Abstract

BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the efficacy and safety of self-administered subcutaneous CSL830 in patients with type I or type II hereditary angioedema who had had four or more attacks in a consecutive 2-month period within 3 months before screening. We randomly assigned the patients to one of four treatment sequences in a crossover design, each involving two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by placebo, or vice versa. The primary efficacy end point was the number of attacks of angioedema. Secondary efficacy end points were the proportion of patients who had a response (≥50% reduction in the number of attacks with CSL830 as compared with placebo) and the number of times that rescue medication was used. RESULTS: Of the 90 patients who underwent randomization, 79 completed the trial. Both doses of CSL830, as compared with placebo, reduced the rate of attacks of hereditary angioedema (mean difference with 40 IU, -2.42 attacks per month; 95% confidence interval [CI], -3.38 to -1.46; and mean difference with 60 IU, -3.51 attacks per month; 95% CI, -4.21 to -2.81; P<0.001 for both comparisons). Response rates were 76% (95% CI, 62 to 87) in the 40-IU group and 90% (95% CI, 77 to 96) in the 60-IU group. The need for rescue medication was reduced from 5.55 uses per month in the placebo group to 1.13 uses per month in the 40-IU group and from 3.89 uses in the placebo group to 0.32 uses per month in the 60-IU group. Adverse events (most commonly mild and transient local site reactions) occurred in similar proportions of patients who received CSL830 and those who received placebo. CONCLUSIONS: In patients with hereditary angioedema, the prophylactic use of a subcutaneous C1 inhibitor twice weekly significantly reduced the frequency of acute attacks. (Funded by CSL Behring; COMPACT EudraCT number, 2013-000916-10 , and ClinicalTrials.gov number, NCT01912456 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1613627

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 240

Metadata

Authors
Longhurst, H., Cicardi, M., Craig, T., Bork, K., Grattan, C., Baker, J., Li, H. H., Reshef, A., Bonner, J., Bernstein, J. A., Anderson, J., Lumry, W. R., Farkas, H., Katelaris, C. H., Sussman, G. L., Jacobs, J., Riedl, M., Manning, M. E., Hebert, J., Keith, P. K., Kivity, S., Neri, S., Levy, D. S., Baeza, M. L., Nathan, R., Schwartz, L. B., Caballero, T., Yang, W., Crisan, I., Hernandez, M. D., Hussain, I., Tarzi, M., Ritchie, B., Králíčková, P., Guilarte, M., Rehman, S. M., Banerji, A., Gower, R. G., Bensen-Kennedy, D., Edelman, J., Feuersenger, H., Lawo, J.-P., Machnig, T., Pawaskar, D., Pragst, I., & Zuraw, B. L.
Venue
New England Journal of Medicine
Published
2017-03-23
Volume
376
Issue
12
Pages
1131-1140
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2599824295
Cited by
240
References
2
FWCI
12.71
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. https://app.cochat.ai/papers/10.1056/nejmoa1613627
The paper
Longhurst, H., Cicardi, M., Craig, T., Bork, K., Grattan, C., Baker, J., Li, H. H., Reshef, A., Bonner, J., Bernstein, J. A., Anderson, J., Lumry, W. R., Farkas, H., Katelaris, C. H., Sussman, G. L., Jacobs, J., Riedl, M., Manning, M. E., Hebert, J., . . . Zuraw, B. L. (2017). Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1613627

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.